医学
无症状的
肾细胞癌
舒尼替尼
肾切除术
外科
阶段(地层学)
纵隔
肺
结核(地质)
癌
放射科
内科学
肾
生物
古生物学
作者
Ovidio Fernández Calvo,Diana Dopico Vázquez,Margarita Reboredo López,Luis Aparicio
出处
期刊:Anti-Cancer Drugs
[Lippincott Williams & Wilkins]
日期:2010-01-01
卷期号:21 (Supplement 1): S17-S18
被引量:8
标识
DOI:10.1097/01.cad.0000361531.59299.5a
摘要
A 63-year-old male, ex-smoker since 2000 underwent left radical nephrectomy in June 2004 after being diagnosed with stage II, pT3bN0M0 clear cell carcinoma. In June 2006, a control CT showed a nodule in the superior lobe, on a peripheral location, and another nodule in the base of the right lung. The patient underwent atypical resections of both nodules, confirming the presence of metastatic disease. In August 2006 the patient started treatment with sunitinib (50 mg/day for 4 weeks, with 2 weeks of rest). A total of nine cycles were administered. Periodic monitoring showed good tolerance, only presenting grade 2 erythrodisesthesia and grade 2 thrombocytopenia. CT studies performed every three cycles showed no evidence of disease recurrence. The last cycle was administered in September 2007 and PET imaging confirmed the absence of recurrence. With the patients consent, treatment was interrupted and periodic radiological and clinical examinations were performed. The patient remained asymptomatic until March 2008 when a control CT revealed an objective progression of the disease at the left lung and mediastinum level. Treatment with sunitinib was restarted at the same doses, completing a total of three cycles, achieving a complete response. The patient is still under treatment.
科研通智能强力驱动
Strongly Powered by AbleSci AI